Last reviewed · How we verify
RO5045377
At a glance
| Generic name | RO5045377 |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RO5045377 CI brief — competitive landscape report
- RO5045377 updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI